Prediction of the pharmacokinetics and adverse events of glecaprevir/pibrentasvir in patients with hepatitis C virus by gadoxetic acid enhanced magnetic resonance imaging
Not Applicable
- Conditions
- Type C chronic hepatitis or type C liver cirrhosis
- Registration Number
- JPRN-UMIN000034251
- Lead Sponsor
- Juntendo University Nerima Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1) Hypersensitivity to Gd-EOB-DTPA 2) Estimated glomerular filtration rate under 40ml/min/1.73m2
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To clarify the relationship between the pretreatment enhancement effect of Gd-EOB-DTPA MRI and the plasma glecaprevir concentration determined 7 days after its administration
- Secondary Outcome Measures
Name Time Method To clarify the relationship between enhancement effect of Gd-EOB-DTPA MRI and development of hyperbilirubinemia during treatment.